MF
NTLA icon

Magnetar Financial’s Intellia Therapeutics NTLA Stock Holding History

Magnetar Financial’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-16,809
Closed -$345K – 736
2024
Q3 		$345K Buy
+16,809
New +$388K 0.01% 379
2024
Q1 		– Sell
-20,780
Closed -$634K – 457
2023
Q4 		$634K Buy
+20,780
New +$597K 0.02% 291
2023
Q1 		– Sell
-45,402
Closed -$1.58M – 684
2022
Q4 		$1.58M Buy
+45,402
New +$2.16M 0.03% 454
2022
Q1 		– Sell
-7,853
Closed -$929K – 1470
2021
Q4 		$929K Buy
+7,853
New +$984K 0.01% 825
2017
Q2 		– Sell
-10,081
Closed -$142K – 914
2017
Q1 		$142K Buy
+10,081
New +$135K ﹤0.01% 688

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Magnetar Financial's NTLA Position: Q4 2024 in Review

Magnetar Financial sold out of Intellia Therapeutics (NTLA) in Q4 2024, closing a stake of 16,809 shares — an estimated $345K sold.

Magnetar Financial first reported a position in NTLA in Q1 2017 and held it in 5 quarters. The position peaked at $1.58M in Q4 2022. 293 funds tracked by Wall St. Rank hold NTLA as of Q4 2024.

  • Magnetar Financial reported no remaining Intellia Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Magnetar Financial sold 16,809 Intellia Therapeutics shares in Q4 2024, an estimated $345K.
  • Magnetar Financial first reported a position in Intellia Therapeutics in Q1 2017 and held it in 5 quarters.
  • Magnetar Financial's Intellia Therapeutics position peaked at $1.58M in Q4 2022.
  • 293 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2024.

Based on Magnetar Financial's 13F filing for Q4 2024, filed 11 Feb 2025.